JPMorgan Chase & Co. Forecasts Strong Price Appreciation for United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics (NASDAQ:UTHR) had its price objective increased by equities researchers at JPMorgan Chase & Co. from $685.00 to $687.00 in a report released on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 30.00% from the stock’s current price.

UTHR has been the topic of several other reports. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. HC Wainwright increased their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Bank of America decreased their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Royal Bank Of Canada boosted their price target on shares of United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Finally, TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $648.33.

United Therapeutics Trading Down 0.2%

Shares of United Therapeutics stock opened at $528.47 on Thursday. The firm has a market capitalization of $22.43 billion, a PE ratio of 19.51, a price-to-earnings-growth ratio of 1.77 and a beta of 0.58. The business’s 50-day moving average price is $547.88 and its 200-day moving average price is $531.39. United Therapeutics has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the business posted $6.63 earnings per share. As a group, analysts predict that United Therapeutics will post 26.63 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $578.58, for a total transaction of $5,785,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,921,276.08. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 513,333 shares of company stock worth $286,933,042 over the last 90 days. 8.60% of the stock is currently owned by insiders.

Institutional Trading of United Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Torren Management LLC purchased a new position in United Therapeutics during the 4th quarter valued at $26,000. Activest Wealth Management lifted its position in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC boosted its stake in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its position in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the period. Finally, Entrust Financial LLC purchased a new position in shares of United Therapeutics during the fourth quarter valued at about $31,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.